{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:50:42Z","timestamp":1791125442475,"version":"4.1.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,12,15]]},"abstract":"<jats:p>Antibodies against human leukocyte antigen (HLA) class II, such as 1D10 or Lym-1, are currently being evaluated for the treatment of B-cell lymphomas. Previous studies have demonstrated that, in addition to IgG Fc receptors, the human myeloid IgA receptor (Fc\u03b1RI, CD89) also effectively triggered tumor cell killing. Therefore, we used the variable light and heavy chain sequences from another murine anti\u2013HLA class II hybridoma, F3.3, to generate a panel of chimeric human\/mouse antibodies, including human immunoglobulin A1 (IgA1), IgA2, IgG1, IgG2, IgG3, and IgG4. Antibody production was accomplished by stable transfection of baby hamster kidney cells, and binding activity and specificity were confirmed by enzyme-linked immunosorbent assay (ELISA) and Western blotting. All constructs demonstrated similar binding to HLA class II. Functional studies revealed that chimeric IgG1, IgA1, and IgA2 triggered similar levels of tumor cell lysis. Analyses of effector populations, however, demonstrated that killing by chimeric IgG1 constructs was triggered mainly by human mononuclear cells and complement, while IgA1 and IgA2 mediated effective lysis by polymorphonuclear neutrophils. Importantly, IgG1 and both IgA isotypes were equally effective at killing freshly isolated human chronic lymphocytic leukemia cells. Chimeric IgA antibodies against HLA class II may constitute attractive reagents for lymphoma therapy.<\/jats:p>","DOI":"10.1182\/blood-2002-03-0687","type":"journal-article","created":{"date-parts":[[2002,11,26]],"date-time":"2002-11-26T13:42:38Z","timestamp":1038318158000},"page":"4574-4580","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":75,"title":["Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing"],"prefix":"10.1182","volume":"100","author":[{"given":"Michael","family":"Dechant","sequence":"first","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gestur","family":"Vidarsson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Stockmeyer","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Repp","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Glennie","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gramatzki","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan G. J.","family":"van de Winkel","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine III, University Erlangen-Nu\u0308rnberg, Erlangen, Germany; the Department of Immunology, University Medical Center Utrecht, The Netherlands; Genmab, Utrecht, The Netherlands; and Tenovus Research Laboratory, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111821124604700_B1","first-page":"461","volume-title":"Unconjugated monoclonal antibodies for the treatment of hematologic and solid malignancies.","author":"Dillman","year":"1999"},{"key":"2019111821124604700_B2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev.med.52.1.125","article-title":"Antibody-targeted immunotherapy for treatment of malignancy.","volume":"52","author":"White","year":"2001","journal-title":"Annu Rev Med."},{"key":"2019111821124604700_B3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","article-title":"Monoclonal antibody-based therapies of leukemia and lymphoma.","volume":"80","author":"Grossbard","year":"1992","journal-title":"Blood."},{"key":"2019111821124604700_B4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0167-5699(00)01669-8","article-title":"Clinical trials of antibody therapy.","volume":"21","author":"Glennie","year":"2000","journal-title":"Immunol Today."},{"key":"2019111821124604700_B5","first-page":"830","article-title":"Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.","volume":"47","author":"Epstein","year":"1987","journal-title":"Cancer Res."},{"key":"2019111821124604700_B6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ijc.1366","article-title":"Humanization and characterization of the anti-HLA-DR antibody 1D10.","volume":"93","author":"Kostelny","year":"2001","journal-title":"Int J Cancer."},{"key":"2019111821124604700_B7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood.V75.12.2408.2408","article-title":"Interferon-\u03b3 augments Lym-1-dependent, granulocyte-mediated tumor cell lysis.","volume":"75","author":"Vaickus","year":"1990","journal-title":"Blood."},{"key":"2019111821124604700_B8","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/blood.V87.12.5171.bloodjournal87125171","article-title":"Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes.","volume":"87","author":"Ottonello","year":"1996","journal-title":"Blood."},{"key":"2019111821124604700_B9","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood.V87.9.3803.bloodjournal8793803","article-title":"HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.","volume":"87","author":"Elsa\u0308sser","year":"1996","journal-title":"Blood."},{"key":"2019111821124604700_B10","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood.V89.6.1996","article-title":"HLA class II-mediated death is induced via Fas\/Fas ligand interactions in human splenic B lymphocytes.","volume":"89","author":"Truman","year":"1997","journal-title":"Blood."},{"key":"2019111821124604700_B11","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.4049\/jimmunol.139.12.4242","article-title":"Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma.","volume":"139","author":"Bridges","year":"1987","journal-title":"J Immunol."},{"key":"2019111821124604700_B12","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood.V90.8.3160","article-title":"Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo.","volume":"90","author":"Funakoshi","year":"1997","journal-title":"Blood."},{"key":"2019111821124604700_B13","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood.V96.10.3544.h8003544_3544_3552","article-title":"Therapeutic efficacy of Fc\u03b3RI\/CD64-directed bispecific antibodies in B-cell lymphoma.","volume":"96","author":"Honeychurch","year":"2000","journal-title":"Blood."},{"key":"2019111821124604700_B14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.6576470","article-title":"Suppressing autoimmunity in mice.","volume":"221","author":"Marx","year":"1983","journal-title":"Science."},{"key":"2019111821124604700_B15","first-page":"1135","article-title":"Phase I study of Hu1D10 monoclonal antibody (Remitogen\u2122) in patients with B-cell lymphoma [abstract].","volume":"20","author":"Link","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"2019111821124604700_B16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/74621","article-title":"Monoclonal antibody therapies-a \u2018constant\u2019 threat to cancer.","volume":"6","author":"Houghton","year":"2000","journal-title":"Nat Med."},{"key":"2019111821124604700_B17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Med."},{"key":"2019111821124604700_B18","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/8426","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.","volume":"5","author":"French","year":"1999","journal-title":"Nat Med."},{"key":"2019111821124604700_B19","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.168.6.2720","article-title":"T-cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.","volume":"168","author":"Tutt","year":"2002","journal-title":"J Immunol."},{"key":"2019111821124604700_B20","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.4049\/jimmunol.164.4.2160","article-title":"Engagement of the OX-40 receptor in vivo enhances antitumor immunity.","volume":"164","author":"Weinberg","year":"2000","journal-title":"J Immunol."},{"key":"2019111821124604700_B21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.194.4.481","article-title":"Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.","volume":"194","author":"van Elsas","year":"2001","journal-title":"J Exp Med."},{"key":"2019111821124604700_B22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc receptors.","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu Rev Immunol."},{"key":"2019111821124604700_B23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med."},{"key":"2019111821124604700_B24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1084\/jem.166.5.1351","article-title":"Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.","volume":"166","author":"Bruggemann","year":"1987","journal-title":"J Exp Med."},{"key":"2019111821124604700_B25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.18.1.739","article-title":"Multiple roles for the major histocompatibility complex class I-related receptor FcRn.","volume":"18","author":"Ghetie","year":"2000","journal-title":"Annu Rev Immunol."},{"key":"2019111821124604700_B26","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/blood.V90.11.4485","article-title":"Fc\u03b1RI (CD89) as a novel trigger molecule for bispecific antibody therapy.","volume":"90","author":"Valerius","year":"1997","journal-title":"Blood."},{"key":"2019111821124604700_B27","first-page":"5778","article-title":"Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.","volume":"59","author":"Huls","year":"1999","journal-title":"Cancer Res."},{"key":"2019111821124604700_B28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/gut.44.1.2","article-title":"Intestinal IgA: novel views on its function in the defence of the largest mucosal surface.","volume":"44","author":"Mestecky","year":"1999","journal-title":"Gut."},{"key":"2019111821124604700_B29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/bj2710285","article-title":"The structure and function of human IgA.","volume":"271","author":"Kerr","year":"1990","journal-title":"Biochem J."},{"key":"2019111821124604700_B30","first-page":"423","article-title":"Structure and function of human IgA Fc receptors (Fc\u03b1R).","volume":"16","author":"Morton","year":"1996","journal-title":"Crit Rev Immunol."},{"key":"2019111821124604700_B31","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood.V93.12.4387","article-title":"Human immunoglobulin A receptor (Fc\u03b1RI, CD89) function in transgenic mice requires both FcR \u03b3 chain and CR3 (CD11b\/CD18).","volume":"93","author":"van Egmond","year":"1999","journal-title":"Blood."},{"key":"2019111821124604700_B32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1471-4906(01)01873-7","article-title":"IgA and the IgA Fc receptor.","volume":"22","author":"van Egmond","year":"2001","journal-title":"Trends Immunol."},{"key":"2019111821124604700_B33","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.165.10.5954","article-title":"Triggering Fc\u03b1-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.","volume":"165","author":"Stockmeyer","year":"2000","journal-title":"J Immunol."},{"key":"2019111821124604700_B34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V97.2.339","article-title":"The intriguing role of polymorphonuclear neutrophils in antitumor reactions.","volume":"97","author":"Di Carlo","year":"2001","journal-title":"Blood."},{"key":"2019111821124604700_B35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-1759(00)00170-8","article-title":"Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments.","volume":"239","author":"Boel","year":"2000","journal-title":"J Immunol Methods."},{"key":"2019111821124604700_B36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0022-1759(00)00337-9","article-title":"Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes.","volume":"249","author":"Vidarsson","year":"2001","journal-title":"J Immunol Methods."},{"key":"2019111821124604700_B37","first-page":"3051","article-title":"Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.","volume":"58","author":"Wu\u0308rflein","year":"1998","journal-title":"Cancer Res."},{"key":"2019111821124604700_B38","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.4049\/jimmunol.151.9.4743","article-title":"Purification and characterization of chimeric human IgA1 and IgA2 expressed in COS and Chinese hamster ovary cells.","volume":"151","author":"Morton","year":"1993","journal-title":"J Immunol."},{"key":"2019111821124604700_B39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1097-0320(20000501)40:1<76::AID-CYTO10>3.0.CO;2-9","article-title":"Binding kinetics of soluble ligands to transmembrane proteins: comparing an optical biosensor and dynamic flow cytometry.","volume":"40","author":"Boulla","year":"2000","journal-title":"Cytometry."},{"key":"2019111821124604700_B40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2567.1996.tb00001.x","article-title":"Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses.","volume":"88","author":"McCloskey","year":"1996","journal-title":"Immunology."},{"key":"2019111821124604700_B41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-1759(00)00346-X","article-title":"Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.","volume":"248","author":"Stockmeyer","year":"2001","journal-title":"J Immunol Methods."},{"key":"2019111821124604700_B42","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.4049\/jimmunol.160.4.1677","article-title":"Bispecific molecules directed to the Fc receptor for IgA (Fc\u03b1RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.","volume":"160","author":"Deo","year":"1998","journal-title":"J Immunol."},{"key":"2019111821124604700_B43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/80886","article-title":"Fc \u03b1\/\u03bc receptor mediates endocytosis of IgM-coated microbes.","volume":"1","author":"Shibuya","year":"2000","journal-title":"Nat Immunol."},{"key":"2019111821124604700_B44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.194.4.417","article-title":"Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy.","volume":"194","author":"Moura","year":"2001","journal-title":"J Exp Med."},{"key":"2019111821124604700_B45","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol."},{"key":"2019111821124604700_B46","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.","volume":"98","author":"Weng","year":"2001","journal-title":"Blood."},{"key":"2019111821124604700_B47","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.","volume":"98","author":"Golay","year":"2001","journal-title":"Blood."},{"key":"2019111821124604700_B48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.immunol.16.1.421","article-title":"Divergent roles for Fc receptors and complement in vivo.","volume":"16","author":"Ravetch","year":"1998","journal-title":"Annu Rev Immunol."},{"key":"2019111821124604700_B49","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphisms in IgG Fc receptor Fc\u03b3RIIIa gene.","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood."},{"key":"2019111821124604700_B50","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc\u03b3RI, Fc\u03b3RII, Fc\u03b3RIII, and FcRn and design of IgG1 variants with improved binding to the Fc\u03b3R.","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem."},{"key":"2019111821124604700_B51","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","article-title":"Engineered antibodies with increased activity to recruit complement.","volume":"166","author":"Idusogie","year":"2001","journal-title":"J Immunol."},{"key":"2019111821124604700_B52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0022-5347(01)69131-6","article-title":"Epidermal growth factor receptor and G250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?","volume":"167","author":"Stadick","year":"2002","journal-title":"J Urol."},{"key":"2019111821124604700_B53","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.4049\/jimmunol.168.7.3275","article-title":"Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity (ADCC).","volume":"168","author":"Tiroch","year":"2002","journal-title":"J Immunol."},{"key":"2019111821124604700_B54","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1073\/pnas.94.14.7509","article-title":"Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.","volume":"94","author":"Ghetie","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821124604700_B55","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood.V97.5.1392","article-title":"Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.","volume":"97","author":"Ghetie","year":"2001","journal-title":"Blood."},{"key":"2019111821124604700_B56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.iy.12.040194.000431","article-title":"Transepithelial transport of immunoglobulins.","volume":"12","author":"Mostov","year":"1994","journal-title":"Annu Rev Immunol."},{"key":"2019111821124604700_B57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1471-4906(01)02032-4","article-title":"Confusion about the polymeric Ig receptor.","volume":"22","author":"Brandtzaeg","year":"2001","journal-title":"Trends Immunol."},{"key":"2019111821124604700_B58","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/76261","article-title":"Fc\u03b1RI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity.","volume":"6","author":"van Egmond","year":"2000","journal-title":"Nat Med."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/13\/4574\/1256309\/h82402004574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/13\/4574\/1256309\/h82402004574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:38:21Z","timestamp":1682350701000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/13\/4574\/106118\/Chimeric-IgA-antibodies-against-HLA-class-II"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,15]]},"references-count":58,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2002,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-03-0687","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1010282.154157","asserted-by":"object"}]},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12,15]]}}}